Drug Guide & Medication · D index

Dovato

Tablet, film coated · Oral · Prescription

Boxed warning

All patients with HIV-1 should be tested for the presence of HBV prior to or when initiating DOVATO. Emergence of lamivudine-resistant HBV variants associated with lamivudine-containing antiretroviral regimens has been reported. If DOVATO is used in patients co-infected with HIV-1 and HBV, additional treatment should be considered for appropriate treatment of chronic HBV; otherwise, consider an alternative regimen.

Severe acute exacerbations of HBV have been reported in patients who are co-infected with HIV-1 and HBV and have discontinued lamivudine, a component of DOVATO. Closely monitor hepatic function in these patients and, if appropriate, initiate anti-HBV treatment [see Warnings and Precautions (5.1)].

Uses

DOVATO is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 25 kg with no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DOVATO.

From the FDA label of Viiv Healthcare Company, version of Oct 29, 2025. Not medical advice: ask your doctor or pharmacist.

Active ingredients

Generic name

Drug class

What it looks like

ImprintLookManufacturer
SV 137White, Oval, 19 mmViiv Healthcare Company

Inactive ingredients and allergens

The labels list none of the common allergens and intolerances (lactose, gluten, gelatin, tartrazine, peanut, soy and others).

From each product's FDA label; they differ between manufacturers and strengths. The app shows every product and finds those without an allergen.

Official FDA label

Read the full label as text, with its contents and search, in the app.

Download Drug Guide & Medication on the App Store

Data: FDA NDC Directory, DailyMed labels, Orange Book, Purple Book and Enforcement Reports, updated Nov 17, 2026.